TABLE 1B.
Acetazolamide treatment and its effect.
| Patient number/Age (y) acetazolamide (ACZ) onset/Treatment lag from seizure onset to acetazolamide (ACZ) treatment(y) | Current dose (mg/kg/d) | Duration years/months | Current ASM | Effect of acetazolamide (ACZ) | Comment |
|---|---|---|---|---|---|
| 1/13/7 | 12 | 3/9 | ACZ | Reduction of myoclonic seizures >90% | Seizures controlled and behavior normalized |
| 2/8/6 | 10 | 1/3 | ACZ | Reduction of myoclonic seizures >75% | Seizures and photosensitivity were fully controlled for 6 months, then seizure reduction >75% remains |
| 3/8/2 | 9 | 0/9 | ACZ | Seizure‐free | Seizures controlled |
| 4/7/5 | 11 | 2/9 | ACZ | Seizure‐free | Seizures controlled |
| 5/17/4 | 15 | 0/9 | ACZ + LEV | Seizure‐free | Seizures controlled |
| 6/13/9 | 6 | 0/6 | ACZ + LEV | Seizure‐free | Photosensitivity controlled and behavior normalized |
| 7/10/7 | 9 | 0/6 | ACZ + LEV | Reduction of myoclonic seizures >75% | Nearly all seizures controlled |
| 8/6/5 | 15 | 0/6 | ACZ + LEV+VPA | Reduction of myoclonic seizures >90% | Nearly all seizures controlled |
| 9/15/14 | 3.5 | 0/6 | ACZ + LEV | Seizure‐free | Photosensitivity controlled |
| 10/4/3.5 | 7.8 | 0/6 | ACZ + LEV + ETX | Reduction of absences with eyelid myoclonus >75% | Seizures and photosensitivity reduced |
| 11/9/2 | 8 | 0/6 | ACZ + LEV | Reduction of myoclonic jerks >75% | Nearly all seizures controlled and photosensitivity reduced |
| 12/17/11 | 5 | 0/6 | ACZ + VPA | Seizure‐free | Photosensitivity controlled |
Abbreviations: ACZ, acetazolamide; m, months; y, years.